AstraZeneca CEO Pascal Soriot says AI could boost late-stage trial success and speed FDA filings, following Wainua's surprise Phase 3 failure.
AstraZeneca’s use of AI in drug design and development has not yet yielded any clinical-stage candidates, CEO Pascal Soriot said Monday, but he added it …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout the…
AstraZeneca posts Q2 pipeline setbacks: mixed ADC data in gastric cancer, an Ultomiris TMA trial miss and an Imfinzi liver cancer…
AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern…
AI is helping life sciences leaders rethink clinical trials by improving dose decisions, patient-level insight, and capital…
It's compressing drug developers' preclinical costs and timelines by as much as 70%.
Drug companies are betting AI can fix the slow, expensive process of testing new drugs in humans.
